Letrozole/Ribociclib Succinate

来曲唑/琥珀酸利柏西利

Report date: 2022/01/14 13:23:58

Base Information

Drug NameLetrozole/Ribociclib Succinate
Drug Alias Name来曲唑/瑞博西尼Ribociclib/LetrozoleRibociclib Succinate/Letrozole瑞博西尼/来曲唑琥珀酸瑞博西尼/来曲唑 +[9] 
ClassificationSmall molecules
Mechanisms of ActionAromatase inhibitorsCyclin-dependent kinase 4 inhibitorsCyclin-dependent kinase 6 inhibitors +[4] 
TargetsAromataseEstrogen receptorsCyclin-dependent kinase 6 +[4] 
Therapy Area/IndicationsBreast Neoplasms
Global Approved IndicationsBreast Neoplasms
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2017/05/04
Country/TerritoryUnited States
CombinationsYes LetrozoleRibociclib Succinate
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesNovartis Pharma Ag
Inactive CompaniesN/A
Active IndicationsBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeL01XE
Related LinksN/A